Spleen‐dedicated stiffness measurement performed well to rule out high‐risk varices in HBV‐related hepatocellular carcinoma

Xiao Cheng,Yujun Tang,Qinjun He,Jiankang Song,Kunyuan Wang,Hui Li,Jing Huang,Weibin Wang,Junying Li,Haiyu Wang,Minghan Tu,Jinzhang Chen,Guosheng Yuan,Shuai Kang,Hongyan Liu,Xiaoyong Zhang,Wenfan Luo,Yali Ji,Xiaoqin Lan,Ling Zhou,Qintao Lai,Xiaoqin Luo,Qiaoping Wu,Damei Zhou,Yingqi Tan,Jinjun Chen,Xiaofeng Zhang
DOI: https://doi.org/10.1111/apt.17850
IF: 9.524
2023-12-30
Alimentary Pharmacology & Therapeutics
Abstract:Spleen‐dedicated stiffness measurement with a cutoff value of 40 kPa performed well to rule out high‐risk varices in HBV‐related hepatocellular carcinoma. Summary Background Esophagogastroduodenoscopy (EGD) is required to screen for high‐risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved with new systemic therapies. Aim To assess the Baveno VI and Baveno VII algorithms' ability to rule out HRV in hepatitis B virus (HBV)‐related HCC Methods We prospectively enrolled consecutive patients with HBV related, compensated cirrhosis and newly diagnosed HCC who underwent liver stiffness measurement, spleen stiffness measurement (SSM) using a 100‐Hz shear wave frequency, and EGD. Results From September 2021 to August 2023, we enrolled 219 patients with HCC, with 107 (48.9%) Barcelona Clinic Liver Cancer (BCLC) A, 28 (12.8%) BCLC B and 84 (38.3%) BCLC C, respectively. HRV prevalence was 28.8% (63/219). Baveno VI criteria safely (HRV missing rate, 3.2%) avoided 27.4% unnecessary EGDs, while the Baveno VII algorithm avoided 49.3% with HRV missing rate at 7.9% (5/63). The SSM ≤40 kPa avoided 47.5% of EGDs safely (HRV missing rate, 4.8%), significantly better than the Baveno VI criteria (p
pharmacology & pharmacy,gastroenterology & hepatology
What problem does this paper attempt to address?